Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ADC Therapeutics Ltd (ADCT)
NYSE:ADCT
Holding ADCT?
Track your performance easily
ADCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.28 - $6.04
Previous Close$1.96
Volume1.90M
Average Volume (3M)792.91K
Market Cap
$204.98M
Enterprise Value$53.76M
Total Cash (Recent Filing)$274.30M
Total Debt (Recent Filing)$123.08M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Mar 13, 2025EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding96,689,617
10 Day Avg. Volume6,845,135
30 Day Avg. Volume792,914
Standard Deviation0.27
R-Squared0.07
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-1.10
Price to Sales (P/S)3.80
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.48
Enterprise Value/Gross Profit0.80
Enterprise Value/Ebitda-0.69
Forecast
1Y Price Target
$7.75Price Target Upside295.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
ADC Therapeutics News
PremiumCompany Announcements
ADC Therapeutics Highlights Q3 Advances and Strategic Focus
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ADCT FAQ
What was ADC Therapeutics Ltd’s price range in the past 12 months?
ADC Therapeutics Ltd lowest stock price was $1.28 and its highest was $6.04 in the past 12 months.
What is ADC Therapeutics Ltd’s market cap?
Currently, no data Available
When is ADC Therapeutics Ltd’s upcoming earnings report date?
ADC Therapeutics Ltd’s upcoming earnings report date is Mar 13, 2025 which is in 81 days.
How were ADC Therapeutics Ltd’s earnings last quarter?
ADC Therapeutics Ltd released its earnings results on Nov 07, 2024. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.395 by -$0.025.
Is ADC Therapeutics Ltd overvalued?
According to Wall Street analysts ADC Therapeutics Ltd’s price is currently Undervalued.
Does ADC Therapeutics Ltd pay dividends?
ADC Therapeutics Ltd does not currently pay dividends.
What is ADC Therapeutics Ltd’s EPS estimate?
ADC Therapeutics Ltd’s EPS estimate is -$0.42.
How many shares outstanding does ADC Therapeutics Ltd have?
ADC Therapeutics Ltd has 96,689,610 shares outstanding.
What happened to ADC Therapeutics Ltd’s price movement after its last earnings report?
ADC Therapeutics Ltd reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.395. Following the earnings report the stock price went down -8.438%.
Which hedge fund is a major shareholder of ADC Therapeutics Ltd?
Among the largest hedge funds holding ADC Therapeutics Ltd’s share is Grosvenor Holdings, L.L.C.. It holds ADC Therapeutics Ltd’s shares valued at 5M.
---
ADC Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.75 (295.41% Upside)
$7.75 (295.41% Upside)
Blogger Sentiment
Bullish
ADCT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 148.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $556.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
53.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-25.23%
Trailing 12-Months
Company Description
ADC Therapeutics Ltd
ADC Therapeutics SA is a United States-based clinical-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ADCT-402, ADCT-301, ADCT-602, and ADCT-601.
---
ADCT Company Deck
---
ADCT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view of ADC Therapeutics' performance. While there are significant achievements in revenue growth, financial stability, and clinical progress, challenges remain with competition in the market and the discontinuation of a solid tumor program. Financial losses continue, but the company's disciplined financial management and strategic focus on ZYNLONTA and promising trials offer a positive outlook.Read More>---
ADCT Stock 12 Month Forecast
Average Price Target
$7.75
▲(295.41% Upside)
Technical Analysis
Best Analysts Covering ADCT
1 Year
1 Year Success Rate
7/19 ratings generated profit
1 Year Average Return
+12.15%
reiterated a buy rating 2 months ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 36.84% of your transactions generating a profit, with an average return of +12.15% per trade.
---